Trailing Twelve Months Revenue Growth: Kazia Therapeutics (KZIA)

Public company logo of Kazia Therapeutics Ltd (KZIA)

Kazia Therapeutics focuses on the treatment of glioblastomas and rare oncological diseases, relying on payments from hospitals and insurance providers. The company enhances drug discovery efficiency through robotic genome analysis and automated cell imaging. Currently, Kazia Therapeutics is developing drugs designed to cross the blood-brain barrier. The TTM annual revenue change illustrates sales dynamics, where the 164.40 level reflects the current magnitude.

Kazia Therapeutics Limited (KZIA): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/19/2026

Kazia Therapeutics Limited - analytical breakdowns and key metrics (KZIA)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:kaziatherapeutics.com
Brand item of kaziatherapeutics.com

Year-over-year (TTM) sales growth measures revenue dynamics over the last twelve months relative to the same period last year, allowing investors to assess business scaling rates and the risk of capital stagnation. By analyzing TTM revenue volatility compared to the previous year, one can benchmark the financial results of Kazia Therapeutics (KZIA) against the operational efficiency of their oncology facilities and the modernization process of their sterile booths.

Who Kazia Therapeutics competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) BioLineRx Corporation (BLRX)|Sales Growth YoY (Last Twelve Months) Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)